Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
Keywords: بی ثباتی ریزماهواره بالا; ALK; anaplastic lymphoma kinase; BRAF; v-Raf murine sarcoma viral oncogene homolog B; cMET; tyrosine-protein kinase Met/hepatocyte growth factor receptor; CT; computer tomography; ECOG; PS Eastern Cooperative Oncology Group performance status; EGFR; epide